Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment

Scandinavian Journal of Rheumatology

Volumn 37, Issue 5, 2008, Pages 399-400

  Brodszky, V ^a   Pentek, M ^b   Gulacsi, L ^a  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b Flór Ferenc Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 52949091844     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740802004966     Document Type: Letter

References (8)

1. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 2007;36:411-17.
2. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents for psoriatic arthritis. Ann Rheum Dis. DOI: 10.1136/ard.2007.072652.
3. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
4. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
5. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50.
6. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
7. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
8. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.